Clinical Trial Update: Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Cadonilimab plus Anlotinib in locally advanced or relapsed/metastatic esophageal squamous cell carcinoma after failure of PD-1…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)
• Cadonilimab

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Esophageal Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN